Osteopenia in Menopause: What It Means and What to Do About It
By Glow Health | Menopause & Sexual Health Specialists
You went for a routine bone density scan and the results came back showing osteopenia. Your clinician may have told you to take calcium, come back in a few years, and not to worry too much. And so you left, not entirely sure what osteopenia actually means, whether it will become osteoporosis, or what you can actually do about it.
This is a scenario that plays out constantly for midlife women, and the "wait and see" approach it often produces is a missed opportunity. Osteopenia is not a minor finding. For women in the menopausal transition, it is a meaningful signal that deserves a real clinical conversation.
What osteopenia is
Bone density is measured using a DEXA scan, which produces a score called a T-score. This score compares your bone density to that of a healthy young adult at peak bone mass.
A T-score of -1.0 or above is considered normal
A T-score between -1.0 and -2.5 is classified as osteopenia
A T-score of -2.5 or below is classified as osteoporosis
Osteopenia means your bone density is lower than the young adult average but not yet in the osteoporosis range. It is not a disease in itself, but it does indicate that bone loss has occurred and that without intervention, the trajectory may continue toward osteoporosis.
It is worth knowing that osteopenia is extremely common in midlife women. Because peak bone mass in women is lower than in men to begin with, and because the menopausal transition accelerates bone loss significantly, a substantial proportion of women in their 40s and 50s will have T-scores in the osteopenic range.
Why menopause accelerates bone loss
Estrogen plays a critical role in maintaining bone density. It regulates the activity of osteoclasts, the cells responsible for breaking down old bone, keeping bone resorption in check. When estrogen declines during perimenopause and menopause, this regulatory brake is released and bone resorption accelerates.
Research from the SWAN study found that women can lose between 10 and 20% of their bone density in the five to seven years surrounding menopause, with the most rapid loss occurring in the two years before and three years after the final menstrual period. This is a substantial and relatively rapid change, and it happens whether or not a woman has symptoms.
This is one reason why bone health deserves attention during perimenopause, not after osteoporosis has already developed. The menopausal transition is a critical window.
What determines your risk
Not all women with osteopenia are at the same risk of progression to osteoporosis or fracture. Factors that increase risk include:
Family history of osteoporosis or fragility fracture
Early menopause or premature ovarian insufficiency
Low body weight or a history of an eating disorder
Smoking
Heavy alcohol use
Long-term use of corticosteroids or certain other medications
Low dietary calcium and vitamin D intake
Sedentary lifestyle
History of eating disorders or low caloric intake over time
Certain medical conditions including rheumatoid arthritis, celiac disease, and inflammatory bowel disease
The FRAX tool, developed by the World Health Organization, calculates a 10-year fracture probability based on clinical risk factors and can be used alongside bone density results to guide treatment decisions.
The difference between osteopenia and osteoporosis treatment
One reason osteopenia is sometimes undertreated is that the prescription medications used for osteoporosis, bisphosphonates like alendronate and others, are not always recommended for women in the osteopenic range unless fracture risk is elevated. This leads some clinicians to conclude there is nothing to do until the T-score crosses the osteoporosis threshold.
But this misses the point. The goal is not to wait until osteoporosis develops and then treat it. The goal is to slow or stop the bone loss that leads there. And for women in the menopausal transition, there are highly effective tools for doing exactly that.
What actually helps
Hormone therapy
Hormone therapy is one of the most effective interventions for preserving bone density during and after the menopausal transition. Estrogen directly inhibits osteoclast activity, slowing bone resorption and helping to maintain the bone density a woman has. A meta-analysis cited by the Endocrine Society found that MHT reduces vertebral fractures by 34%, hip fractures by 29%, and nonvertebral fractures by 21%, which is a clinically significant benefit that holds up across the risk spectrum.
Most guidelines position hormone therapy primarily as a bone preservation strategy in recently menopausal women, reserving bisphosphonates, denosumab, and osteoanabolic agents for established osteoporosis. However, this distinction is increasingly questioned. European experts in particular argue that MHT should be considered a first-line option for bone health in early postmenopausal women. And the evidence strongly supports that estrogen increases bone mineral density even in women with established osteoporosis, not just those in the osteopenic range.
The most compelling evidence comes from Lufkin et al. (1992), the only placebo-controlled trial specifically enrolling women with established osteoporosis and vertebral fractures. Transdermal estradiol 0.1 mg over one year produced a 61% reduction in new vertebral fractures and a 5.3% increase in lumbar spine BMD. Notably, estrogen is the only anti-osteoporotic therapy with demonstrated fracture reduction regardless of baseline fracture risk, including in lower-risk women, a distinction no bisphosphonate or denosumab trial has shown, as those trials enrolled only higher-risk populations.
In clinical practice, women with osteopenia or osteoporosis who are also experiencing menopausal symptoms are excellent candidates for hormone therapy, which addresses both bone health and symptom relief simultaneously. For women with established osteoporosis, hormone therapy can be a meaningful part of the treatment plan, with the understanding that a transition to dedicated osteoporosis therapy may be considered as part of ongoing care.
Calcium and vitamin D
Calcium and vitamin D are foundational for bone health, but it's worth being clear about what the evidence actually shows. Together, they provide a modest reduction in hip fracture risk, primarily in older women, those in care settings, or those who are vitamin D deficient. Vitamin D alone, in women who are not deficient, has not been shown to reduce fractures on its own. They are not a substitute for other interventions, but they are an important foundation, particularly for women taking osteoporosis medications, since virtually all the major drug trials in this area included calcium and vitamin D as part of the treatment protocol.
Current recommendations for postmenopausal women are generally 1,200 mg of calcium per day from food and supplements combined, and 800 to 1,000 IU of vitamin D daily, though individual needs vary. Food sources of calcium, including dairy, fortified plant milks, leafy greens, and canned fish with bones, are preferable to supplements where possible. High-dose calcium supplementation has been associated with a modest increase in kidney stones and, in some studies, cardiovascular events, so getting calcium from food first and supplementing only the gap is the sensible approach. Vitamin D is difficult to obtain from food alone and many women in midlife are deficient, making supplementation commonly necessary.
Resistance training and weight-bearing exercise
Bone is living tissue that responds to mechanical load. Weight-bearing exercise and resistance training stimulate bone formation and help maintain bone density. Activities like walking, hiking, dancing, and strength training all contribute. Balance and coordination training is also valuable because it reduces fall risk, which is ultimately what determines whether low bone density leads to a fracture.
A 2022 review in Osteoporosis International found that progressive resistance training was among the most effective exercise modalities for improving bone density at the hip and spine in postmenopausal women, with benefits beyond what aerobic exercise alone provides.
Lifestyle factors
Smoking is directly toxic to bone and quitting is one of the most impactful things a smoker can do for their skeletal health. Excessive alcohol consumption impairs bone formation and increases fall risk. Both deserve direct clinical attention in women with osteopenia.
Pharmacological treatment
For women with osteopenia whose FRAX score indicates elevated fracture risk, or who have other significant risk factors, prescription treatment may be appropriate even before the osteoporosis threshold is reached. This is a decision that should be made on an individual basis with a clinician who reviews the full risk picture.
A follow-up DEXA scan is typically recommended every one to two years for women with osteopenia to monitor trajectory, though the timing depends on individual circumstances.
How Glow Health can help
At Glow Health, we view bone health as an integral part of menopause care, not a separate specialty concern. We discuss bone density, fracture risk, and preventive strategies as part of a comprehensive approach to midlife health, and we work with you on an individualized plan that takes your full picture into account.
If you've received a diagnosis of osteopenia and are looking for a more thorough conversation about what it means and what to do about it, we'd welcome that discussion.
Keywords: osteopenia menopause, osteopenia treatment, bone density menopause, menopause and bone loss, osteopenia vs osteoporosis, DEXA scan menopause, estrogen and bone density, preventing osteoporosis menopause
This post is for informational purposes only and does not constitute medical advice. Please consult a qualified healthcare clinician for personalized guidance.
